List of Excipients in Branded Drug STIMUFEND

« Back to Dashboard

STIMUFEND Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 8, 2026

STIMUFEND is Fresenius Kabi’s pegfilgrastim-fpgk biosimilar to Neulasta, supplied as a 6 mg/0.6 mL single-dose prefilled syringe. Its formulation uses a conventional aqueous biologic platform built around acetate, polysorbate 20, sorbitol, and water for injection. The commercial opportunity is concentrated in supply reliability, biosimilar contracting, prefilled-syringe manufacturing, cold-chain execution, and potential presentation expansion rather than in a novel excipient claim.

STIMUFEND is not a small-molecule generic. It was approved through the FDA’s 351(k) biosimilar pathway on September 20, 2022. The product does not have an Orange Book patent listing because biologics are tracked primarily through the Purple Book and related patent-dispute procedures under the Biologics Price Competition and Innovation Act, or BPCIA.[1,2]

What is STIMUFEND and how is it formulated?

STIMUFEND is pegfilgrastim-fpgk, a long-acting granulocyte colony-stimulating factor used to reduce the incidence of infection, as manifested by febrile neutropenia, in patients receiving myelosuppressive anticancer chemotherapy.[3]

Attribute	STIMUFEND
Active ingredient	Pegfilgrastim-fpgk
Reference product	Neulasta, pegfilgrastim
Sponsor	Fresenius Kabi USA, LLC
FDA pathway	351(k) biosimilar application
FDA approval	September 20, 2022
Dose	6 mg subcutaneously once per chemotherapy cycle
Presentation	Single-dose prefilled syringe
Fill volume	0.6 mL
Storage	Refrigerated at 2°C to 8°C; protect from light; do not freeze
Administration timing	At least 24 hours after cytotoxic chemotherapy and at least 14 days before the next cycle
Interchangeability	No FDA interchangeable designation identified in the FDA product labeling
Orange Book listing	Not applicable as a biologic
Purple Book reference product	Neulasta

The US prescribing information identifies acetate, polysorbate 20, sorbitol, and water for injection as inactive ingredients. The formulation pH is adjusted as needed during manufacture.[3]

What excipients protect STIMUFEND stability?

The excipient system has four principal functions:

Excipient	Primary formulation role	Commercial and technical relevance
Acetate	Buffering and pH control	Helps maintain a pH range compatible with pegfilgrastim stability
Polysorbate 20	Surfactant	Limits adsorption and interfacial aggregation during filling, storage, and injection
Sorbitol	Tonicity adjustment and stabilizing polyol	Supports osmolality and may reduce stress from freezing, concentration, and interfaces
Water for injection	Vehicle	Provides the aqueous phase for the injectable product

Polysorbate 20 is the most strategically sensitive excipient. In protein formulations, surfactant degradation can generate peroxides and other reactive species that may affect protein quality. Supplier control, peroxide specifications, incoming testing, and storage conditions therefore have greater importance than the low concentration of the excipient might suggest.

Sorbitol provides a relatively familiar tonicity and stabilization approach. A change to another polyol, sugar, or amino-acid-based stabilizer could alter viscosity, osmolality, aggregation, subvisible particles, syringeability, and comparability. Such changes would require a substantial analytical package and could affect biosimilarity conclusions.

Acetate is technically conventional but commercially important. Buffer concentration and pH influence deamidation, oxidation, aggregation, injection tolerability, and compatibility with the container closure system. A modified buffer system could create a differentiated formulation, but the regulatory burden would rise if the change affects critical quality attributes.

What formulation strategy does STIMUFEND use?

STIMUFEND uses a low-complexity formulation strategy rather than a differentiated delivery platform. The approach has four commercial advantages:

1. It minimizes excipient novelty and associated regulatory risk.
2. It aligns with the reference product’s established route and presentation.
3. It supports comparability to a well-characterized pegfilgrastim product.
4. It permits use of standard prefilled-syringe filling and refrigerated distribution infrastructure.

The strategy also limits differentiation. A conventional formulation makes it harder to justify a premium based solely on excipients. The principal value proposition must therefore come from price, supply, contracting, service, device execution, and healthcare-provider confidence.

What are the main formulation risks?

The critical risks are protein aggregation, oxidation, surfactant degradation, particulate formation, container closure interaction, and temperature excursions.

A sponsor or contract manufacturer evaluating STIMUFEND-related opportunities should monitor:

• High-molecular-weight species and soluble aggregates
• Subvisible and visible particles
• Oxidation and deamidation of the protein
• Polysorbate 20 concentration and degradation products
• pH and osmolality drift
• Extractables and leachables from the prefilled syringe
• Silicone oil interaction with the protein
• Needle force, glide force, and injection time
• Stability after removal from refrigeration
• Light exposure and accidental freezing

The prefilled syringe adds a device layer to the excipient strategy. Silicone oil, tungsten residues from syringe manufacture, elastomer components, needle adhesives, and barrel materials can affect protein quality. Device and formulation development therefore cannot be managed as separate workstreams.

What commercial opportunities exist for STIMUFEND excipients?

The strongest opportunities are in supply assurance, quality control, and presentation development.

Excipient supply and dual sourcing

Polysorbate 20 and sorbitol are widely available, but biologic-grade supply requires tighter control than commodity procurement. A supplier that can provide low-peroxide polysorbate 20, consistent molecular-weight distribution, validated microbial control, and lot-to-lot documentation can create value through qualification and continuity.

A dual-source strategy can reduce shortage risk but may trigger bridging studies. The key issue is not simply chemical identity. It is the effect of supplier-specific impurity profiles on pegfilgrastim stability and particle formation.

Stabilized surfactant systems

A supplier may seek to offer a stabilized polysorbate 20 grade with reduced peroxide burden or improved control of hydrolysis products. The opportunity is technically credible but commercially constrained by the need to preserve the approved product’s quality profile.

A change in polysorbate source could require:

• Side-by-side stability
• Forced-degradation studies
• Subvisible-particle testing
• Oxidative impurity assessment
• Container closure compatibility
• Process validation
• Regulatory comparability documentation

This is more likely to create a supply or manufacturing advantage than a standalone product patent.

Prefilled-syringe manufacturing

The prefilled syringe is a larger commercial opportunity than a new excipient claim. Contract manufacturers can compete on:

• Fill-finish capacity
• Low-volume biologic filling
• Particulate control
• Device consistency
• Automated inspection
• Cold-chain packaging
• Serialization and traceability
• Backup capacity for oncology supply

The dosage is administered once per chemotherapy cycle, creating predictable demand linked to oncology treatment volumes. Hospitals and specialty distributors may value continuity of supply more than minor formulation differences.

Alternative delivery presentations

Potential future presentations include an on-body injector, an autoinjector, or a higher-convenience prefilled device. These products would not be simple excipient substitutions. They would require human-factors work, device compatibility testing, extractables and leachables assessment, dose-delivery validation, and regulatory review.

An on-body or wearable presentation could create a stronger commercial position than a formulation-only change because it may reduce administration burden. The development cost and device failure risk would also be higher.

How strong is the STIMUFEND patent estate?

STIMUFEND’s commercial protection is primarily regulatory and manufacturing-based rather than dependent on a broad proprietary excipient platform.

Protection category	Relevance to STIMUFEND
Reference-product patents	Addressed through BPCIA patent procedures and any negotiated settlement
Biosimilar regulatory exclusivity	Limited by the statutory framework for biologics
Product-specific formulation patents	Possible, but no broad STIMUFEND excipient patent position is established by the prescribing information
Device patents	Potentially relevant to the prefilled syringe or future delivery systems
Manufacturing know-how	Likely important for yield, aggregation control, filling, and release testing
Supplier agreements	Can create practical barriers to rapid replication
Trade secrets	May protect cell line, purification, formulation process, and analytical methods

A biosimilar’s approved formulation is not automatically protected by a patent. The use of acetate, polysorbate 20, sorbitol, and water for injection is conventional. Patentability would depend on a novel and non-obvious combination, a specific concentration range, a stability result, a container interaction, or a manufacturing process that is adequately claimed and enabled.

What patents protect the reference product?

Neulasta-related patent protection has historically included patents covering pegylated G-CSF compositions, methods, formulations, and manufacturing technologies. The relevant legal analysis depends on the patent family, claim scope, terminal disclaimers, patent-term adjustments, pediatric extensions, and any BPCIA settlement.

The FDA Purple Book does not function as a complete patent database. Patent status must be assessed through USPTO records, court dockets, settlement documents, and the reference-product sponsor’s patent disclosures.[2,4]

What is the FDA regulatory status of STIMUFEND?

STIMUFEND is FDA-approved as a biosimilar to Neulasta. Biosimilarity means there are no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency.[1,3]

Approval does not mean automatic pharmacy substitution. An interchangeable biosimilar must meet an additional statutory standard showing that switching between the biosimilar and reference product is not expected to produce greater risk than using the reference product without switching. STIMUFEND’s labeling does not identify an interchangeable designation.[3]

The product’s regulatory opportunity is therefore strongest in oncology accounts where physicians, health systems, payers, and specialty distributors can adopt a non-interchangeable biosimilar through formulary, contracting, or prescribing decisions.

Which companies compete with STIMUFEND?

The US pegfilgrastim biosimilar market includes several products with overlapping clinical use and different commercial positions.

Product	Sponsor	Active ingredient	General competitive position
Neulasta	Amgen	Pegfilgrastim	Reference product
STIMUFEND	Fresenius Kabi	Pegfilgrastim-fpgk	Biosimilar with prefilled-syringe presentation
Ziextenzo	Sandoz	Pegfilgrastim-bmez	Established biosimilar competitor
Udenyca	Coherus BioSciences	Pegfilgrastim-cbqv	Biosimilar with broad commercial presence and multiple presentations
Fulphila	Biocon Biologics and partners	Pegfilgrastim-jmbd	Biosimilar competitor
Nyvepria	Pfizer	Pegfilgrastim-apgf	Biosimilar competitor
Fylnetra	Lupin	Pegfilgrastim-pbbk	Biosimilar competitor

Competition is based on net price, payer access, wholesaler terms, inventory reliability, provider preference, presentation, and launch timing. Excipients are unlikely to determine market share unless they affect stability, injection experience, shelf life, or supply continuity.

What generic and biosimilar entry risks affect STIMUFEND?

STIMUFEND faces five principal risks:

1. Price erosion: Multiple pegfilgrastim biosimilars can compress gross-to-net pricing.
2. Contract concentration: A small number of group purchasing organizations and specialty distributors can influence access.
3. Reference-product defense: Patent litigation, settlement terms, and launch restrictions can affect timing.
4. Manufacturing variability: Biologic yield, aggregation, fill-finish deviations, and cold-chain failures can impair supply.
5. Interchangeability competition: A future interchangeable pegfilgrastim could obtain stronger substitution advantages.

The product is less exposed to conventional generic substitution than an oral small molecule. Its commercial risk is controlled by clinical adoption and channel economics rather than pharmacy-level automatic substitution alone.

What licensing and partnership opportunities exist?

Licensing opportunities are most credible in four areas:

Regional commercialization

A regional partner could provide oncology sales infrastructure, payer contracting, specialty distribution, and hospital access. This is relevant in markets where Fresenius Kabi lacks direct commercial reach or where local tender systems determine volume.

Device technology

A partner with an autoinjector or on-body delivery platform could support a differentiated presentation. The value would depend on clinical workflow improvements and payer willingness to reimburse a higher-cost device.

Formulation and fill-finish technology

A formulation technology that improves refrigerated shelf life, excursion tolerance, or syringe compatibility could reduce logistics costs. The technology would need to preserve biosimilarity and avoid creating a new particulate or immunogenicity risk.

Manufacturing capacity

Contract manufacturing partnerships can address peak demand, redundancy, and geographic supply requirements. For a biologic administered in oncology clinics, a second qualified fill-finish site can have strategic value even without a new patent.

What is the likely commercial outlook?

STIMUFEND’s commercial opportunity is a scale and execution opportunity. The excipient system is familiar, inexpensive relative to the active ingredient, and unlikely to support a major premium. The highest-value actions are:

• Secure qualified dual sources for polysorbate 20 and sorbitol.
• Establish tight surfactant peroxide and degradation specifications.
• Control syringe-related particles and protein adsorption.
• Build redundant fill-finish capacity.
• Use stability data to support distribution and inventory flexibility.
• Evaluate an autoinjector or on-body presentation.
• Protect manufacturing improvements through process patents and trade secrets.
• Compete on net price, supply assurance, and account-level contracting.
• Monitor interchangeable biosimilar launches and payer preference shifts.

The strongest patent position would likely come from a specific formulation or device configuration with demonstrated stability or usability advantages, not from the basic use of acetate, polysorbate 20, sorbitol, and water.

Key Takeaways

• STIMUFEND is pegfilgrastim-fpgk, a Neulasta biosimilar approved by the FDA in September 2022.
• Its formulation contains acetate, polysorbate 20, sorbitol, and water for injection.
• Polysorbate 20 quality, oxidation control, and syringe compatibility are the principal excipient risks.
• The product is supplied in a 6 mg/0.6 mL single-dose prefilled syringe.
• STIMUFEND is not identified as an interchangeable biosimilar in its FDA labeling.
• Biologic patent analysis relies on Purple Book, USPTO, BPCIA, and court records rather than Orange Book listings.
• The most attractive commercial opportunities are supply assurance, fill-finish capacity, device differentiation, and oncology contracting.
• Conventional excipients alone are unlikely to create durable premium pricing or a broad patent moat.
• Manufacturing know-how, container closure control, and device execution may be more commercially defensible than the excipient composition.

FAQs

Does STIMUFEND contain polysorbate 20?

Yes. FDA labeling identifies polysorbate 20 as an inactive ingredient in STIMUFEND.[3]

Can STIMUFEND be automatically substituted for Neulasta?

Not solely because it is a biosimilar. Automatic substitution depends on an FDA interchangeable designation and applicable state pharmacy law. STIMUFEND’s labeling does not identify interchangeability.[3]

Is STIMUFEND an Orange Book product?

No. STIMUFEND is a biologic. Its regulatory and patent framework is associated with the Purple Book and BPCIA procedures rather than the small-molecule Orange Book system.[1,2]

Can a new excipient create a patent for a pegfilgrastim biosimilar?

Possibly, but the excipient must be part of a novel, non-obvious, adequately enabled formulation or process claim. Conventional acetate, polysorbate 20, sorbitol, and water are unlikely to create broad protection without a specific technical advantage.

What is the largest commercial opportunity around STIMUFEND?

The largest opportunities are likely to come from reliable biologic fill-finish, qualified excipient sourcing, device improvements, and payer or hospital contracting. A new excipient by itself is less likely to materially change market share.

References

1. U.S. Food and Drug Administration. (2023). Biosimilar and interchangeable biosimilar products. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars

2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

3. U.S. Food and Drug Administration. (2022). STIMUFEND (pegfilgrastim-fpgk) injection, prescribing information. Fresenius Kabi USA, LLC.

4. United States Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/